The FDA announced it will permit continued sales of textured breast implants, which were recently tied to breast-implant-associated anaplastic large cell lymphoma. However, the agency may consider adding a black box warning and is working with patient groups and manufacturers on label changes.
FDA allows continued sale of breast implants linked to cancer
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.